0001893645 false 2026-06-30 Q2 --12-31 0001893645 2026-01-01 2026-06-30 0001893645 us-gaap:PrivatePlacementMember plrz:PIPEOrdinaryWarrantsMember srt:ScenarioForecastMember 2026-09-04 0001893645 us-gaap:PrivatePlacementMember plrz:PIPEOrdinaryWarrantsMember srt:ScenarioForecastMember 2026-09-04 2026-09-04 0001893645 us-gaap:PrivatePlacementMember plrz:PreFundedWarrantsMember srt:ScenarioForecastMember 2026-09-04 2026-09-04 0001893645 us-gaap:IPOMember plrz:PreFundedWarrantsMember srt:ScenarioForecastMember 2026-09-04 0001893645 us-gaap:IPOMember us-gaap:CommonStockMember srt:ScenarioForecastMember 2026-09-04 0001893645 us-gaap:IPOMember plrz:PreFundedWarrantsMember srt:ScenarioForecastMember 2026-09-04 2026-09-04 0001893645 us-gaap:IPOMember us-gaap:CommonStockMember srt:ScenarioForecastMember 2026-09-04 2026-09-04 0001893645 srt:ScenarioForecastMember 2026-09-04 0001893645 srt:ScenarioForecastMember 2026-09-04 2026-09-04 0001893645 us-gaap:SubsequentEventMember plrz:QuantumXLabsIncMember 2026-07-02 2026-07-02 0001893645 us-gaap:SubsequentEventMember plrz:QuantumXLabsIncMember 2026-07-02 0001893645 2025-01-01 2025-06-30 0001893645 plrz:ExchangeWarrantsMember 2025-01-01 2025-06-30 0001893645 plrz:ExchangeWarrantsMember 2026-01-01 2026-06-30 0001893645 plrz:SeriesAWarrantsMember 2025-01-01 2025-06-30 0001893645 plrz:April2026WarrantsMember 2026-01-01 2026-06-30 0001893645 plrz:IPOWarrantsMember 2025-01-01 2025-06-30 0001893645 plrz:IPOWarrantsMember 2026-01-01 2026-06-30 0001893645 plrz:OptionsMember 2025-01-01 2025-06-30 0001893645 plrz:OptionsMember 2026-01-01 2026-06-30 0001893645 us-gaap:ServiceMember 2026-01-01 2026-06-30 0001893645 plrz:GeneralAndAdministrativeExpensesMember 2025-01-01 2025-06-30 0001893645 plrz:GeneralAndAdministrativeExpensesMember 2026-01-01 2026-06-30 0001893645 plrz:ResearchAndDevelopmentExpensesMember 2025-01-01 2025-06-30 0001893645 plrz:ResearchAndDevelopmentExpensesMember 2026-01-01 2026-06-30 0001893645 2026-05-14 2026-05-14 0001893645 srt:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2026-07-13 2026-07-13 0001893645 us-gaap:RestrictedStockUnitsRSUMember 2026-05-14 2026-05-14 0001893645 plrz:TwoThousandTwentyOnePlanMember 2026-06-30 0001893645 us-gaap:CommonStockMember 2025-11-28 0001893645 2025-11-28 2025-11-28 0001893645 us-gaap:CommonStockMember 2025-11-28 2025-11-28 0001893645 plrz:PIPEOrdinaryWarrantsMember 2026-06-30 0001893645 us-gaap:WarrantMember 2026-04-08 0001893645 plrz:PIPEPrefundedWarrantsMember 2026-04-08 0001893645 plrz:PreFundedWarrantsMember 2026-04-08 2026-04-08 0001893645 us-gaap:CommonStockMember 2026-04-08 2026-04-08 0001893645 us-gaap:PrivatePlacementMember 2026-04-08 2026-04-08 0001893645 plrz:ConsultantsMember 2026-03-31 2026-03-31 0001893645 us-gaap:CommonStockMember plrz:ConsultantsMember 2026-03-31 2026-03-31 0001893645 us-gaap:RestrictedStockUnitsRSUMember 2026-06-30 0001893645 2025-06-30 0001893645 2024-12-31 0001893645 2026-06-30 0001893645 2025-12-31 0001893645 us-gaap:LicenseMember 2026-06-30 0001893645 plrz:LicenseAgreementMember 2026-06-30 0001893645 us-gaap:WarrantMember 2026-01-01 2026-06-30 0001893645 plrz:PreFundedWarrantsMember 2026-01-01 2026-06-30 0001893645 us-gaap:IPOMember 2026-01-01 2026-06-30 0001893645 plrz:SciSparcMember us-gaap:CommonStockMember 2026-01-01 2026-06-30 0001893645 plrz:AdditionalJurisdictionClinicalMember 2024-08-13 2024-08-13 0001893645 plrz:EURegulatoryBodyMember 2024-08-13 2024-08-13 0001893645 plrz:FDAMember 2024-08-13 2024-08-13 0001893645 plrz:Phase3ClinicalTrialsMember 2024-08-13 2024-08-13 0001893645 plrz:Phase2bClinicalTrialMember 2024-08-13 2024-08-13 0001893645 plrz:Phase2aClinicalTrialMember 2024-08-13 2024-08-13 0001893645 plrz:Phase1ClinicalTrialMember 2024-08-13 2024-08-13 0001893645 plrz:PreclinicalSafetyTestMember 2024-08-13 2024-08-13 0001893645 2024-08-13 2024-08-13 0001893645 plrz:MeasurementInputFairValueMember us-gaap:FairValueInputsLevel3Member 2026-06-30 0001893645 us-gaap:MeasurementInputExpectedTermMember us-gaap:FairValueInputsLevel3Member 2026-06-30 0001893645 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:FairValueInputsLevel3Member 2026-06-30 0001893645 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:FairValueInputsLevel3Member 2026-06-30 0001893645 us-gaap:MeasurementInputSharePriceMember us-gaap:FairValueInputsLevel3Member 2026-06-30 0001893645 plrz:MeasurementInputNumberOfWarrantsMember us-gaap:FairValueInputsLevel3Member 2026-06-30 0001893645 plrz:QuantumXLabsIncMember 2026-01-01 2026-06-30 0001893645 plrz:QuantumXLabsIncMember 2026-07-02 0001893645 plrz:QuantumXLabsIncMember 2026-03-04 0001893645 plrz:QuantumXLabsIncMember 2025-01-01 2025-12-31 0001893645 plrz:TaurusGoldCorpMember 2026-01-01 2026-06-30 0001893645 plrz:TaurusGoldCorpMember 2026-06-30 0001893645 plrz:TaurusGoldCorpMember 2025-10-24 0001893645 plrz:TaurusGoldCorpMember 2025-10-24 2025-10-24 0001893645 plrz:TaurusGoldCorpMember us-gaap:CommonStockMember 2025-10-24 2025-10-24 0001893645 plrz:TaurusGoldCorpMember 2025-10-10 2025-10-10 0001893645 plrz:TaurusGoldCorpMember us-gaap:CommonStockMember 2025-10-10 2025-10-10 0001893645 us-gaap:RetainedEarningsMember 2026-06-30 0001893645 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001893645 us-gaap:CommonStockMember 2026-06-30 0001893645 us-gaap:RetainedEarningsMember 2026-01-01 2026-06-30 0001893645 us-gaap:CommonStockMember 2026-01-01 2026-06-30 0001893645 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-06-30 0001893645 us-gaap:RetainedEarningsMember 2025-12-31 0001893645 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001893645 us-gaap:CommonStockMember 2025-12-31 0001893645 us-gaap:RetainedEarningsMember 2025-06-30 0001893645 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001893645 us-gaap:CommonStockMember 2025-06-30 0001893645 us-gaap:RetainedEarningsMember 2025-01-01 2025-06-30 0001893645 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-06-30 0001893645 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0001893645 us-gaap:RetainedEarningsMember 2024-12-31 0001893645 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001893645 us-gaap:CommonStockMember 2024-12-31 0001893645 plrz:SeriesAWarrantsMember 2026-01-01 2026-06-30 0001893645 plrz:April2026WarrantsMember 2025-01-01 2025-06-30 iso4217:USD xbrli:shares xbrli:shares iso4217:USD xbrli:pure iso4217:CAD xbrli:shares iso4217:CAD

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of September 2026

 

Commission file number: 001-42375

 

Polyrizon Ltd.

(Translation of registrant’s name into English)

 

5 Ha-Tidhar Street

Raanana, 4366507, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒        Form 40-F ☐

 

 

 

 

 

 

CONTENTS

 

This Report of Foreign Private Issuer on Form 6-K consists of (i) the Registrant’s Interim Condensed Financial Statements as of June 30, 2026, which is attached hereto as Exhibit 99.1; and (ii) the Registrant’s Management’s Discussion and Analysis of Financial Condition and Results of Operations for the six months ended June 30, 2026, which is attached hereto as Exhibit 99.2.

 

Exhibit 99.2, Exhibit 99.3 attached to this Form 6-K are incorporated by reference into the Registrant’s Registration Statements on Form S-8 (File No. 333-284410 and 333-288923) and Form F-3 (333-291368), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

1

 

 

EXHIBIT INDEX

 

Exhibit No.    
99.1   Polyrizon Ltd.’s Interim Condensed Financial Statements as of June 30, 2026.
99.2   Polyrizon Ltd.’s Management’s Discussion and Analysis of Financial Condition and Results of Operations for the six months ended June 30, 2026.
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
104   Cover Page Interactive Data File formatted as Inline XBRL and contained in Exhibit 101

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Polyrizon Ltd.
   
Date: September 28, 2026 By: /s/ Tomer Izraeli
  Name: Tomer Izraeli
  Title: Chief Executive Officer

 

3